Epigenomics' competitor Oncomethylome Sciences on November 19, 2007 published first own data on the early detection of colorectal cancer in blood using a panel of four DNA methylation biomarkers. The preliminary performance data of this panel presented are essentially identical with the performance of Epigenomics' blood test for colorectal cancer early detection based on the biomarker Septin 9 that was validated in numerous studies. The data provide independent validation of the feasibility of a simple and reliable blood test for colorectal cancer screening based on DNA methylation. Nevertheless, Epigenomics is convinced that the Septin 9 test is the by far more advanced product in development and better positioned from an economic point of view. A summary of Epigenomics' position is available here.

###

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.